Core sales growth - Biotechnology was 2.5% in Q2 FY26, the quarter ended 26 Jun 2026.
| Fiscal quarter | Quarter ended | Value | Year over year |
|---|---|---|---|
| Q2 FY26 | 2026-06-26 | 2.5% | -58.3% |
| Q1 FY26 | 2026-03-27 | 7% | +0.0% |
| Q4 FY25 | 2025-12-31 | 6% | -25.0% |
| Q3 FY25 | 2025-09-26 | 6.5% | — |
| Q2 FY25 | 2025-06-27 | 6% | — |
| Q1 FY25 | 2025-03-28 | 7% | — |
| Q4 FY24 | 2024-12-31 | 8% | — |
| Q3 FY24 | 2024-09-27 | 0% | — |
Year over year is shown where the same quarter a year earlier is in the eight. Every quarter back to the first report, with CSV, is in the research platform.
Danaher reports this as “Core sales growth - Biotechnology” in its earnings materials. Stock Atlas keeps the company's own label and does not restate it to match other companies.
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Danaher Core sales growth - Biotechnology by quarter”, stockatlas.com/companies/DHR/kpi/core-sales-growth-biotechnology/, data as of 3 November 2026. Links to this page are welcome.
